Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience

Clinical Infectious Diseases

Volumn 63, Issue 4, 2016, Pages 519-527

  Garland, Suzanne M ^a   Kjaer, Susanne K ^b   Muñoz, Nubia ^c   Block, Stan L ^d   Brown, Darron R ^e   Dinubile, Mark J ^f   Lindsay, Brianna R ^f   Kuter, Barbara J ^f   Perez, Gonzalo ^f,g   Dominiak Felden, Geraldine ^h   Saah, Alfred J ^f   Drury, Rosybel ^h   Das, Rituparna ^f   Velicer, Christine ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Instituto Nacional de Cancerología   (Colombia)

^d Kentucky Pediatric Research Institute   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSIDAD DEL ROSARIO   (Colombia)

^h SANOFI PASTEUR   (France)

Author keywords

Cervical cancer; CIN; Gardasil Silgard; Genital warts; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

CLINICAL EFFECTIVENESS; CONDYLOMA ACUMINATUM; DRUG EXPOSURE; EMBASE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MEDLINE; OBSERVATIONAL STUDY; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; FEMALE; IMMUNOLOGY; MALE; PAPILLOMAVIRIDAE; UTERINE CERVIX TUMOR; VIROLOGY;

CONDYLOMATA ACUMINATA; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84982168442     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw354     Document Type: Review

References (40)

1. Forman D, de Martel C, Lacey C, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30S:F12-3
2. World Health Organization. Human papillomavirus (HPV) and cervical cancer. Available at: http://www.who.int/mediacentre/factsheets/fs380/en/. Accessed 24 February 2016
3. Joura E, Ault K, Bosch X, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014; 23:1997-2008
4. Alemany L, Cubilla A, Halec G, et al. Role of HPV in penile carcinomas worldwide. Eur Urol 2016; doi:10.1016/j.eururo.2015.12.007
5. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136:98-107
6. Alemany M, Saunier L, Tinoco B, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Euro J Cancer 2014; 50:2846-54
7. Castellsague X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: a comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 2016; doi:10.1093/jnci/djv403
8. De Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450-61
9. Gillison M, Castellsague X, Chaturvedi A, et al. EUROGIN roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 2014; 134:497-507
10. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13:607-15
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917
12. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-56
13. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301
14. Saraiya M, Unger ER, Thompson TD, et al. HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015; 107:djv086
15. Garland SM, StebenM, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. J Infect Dis 2009; 119:805-14
16. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents versus 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802
17. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23
18. World Health Organization. Countries with HPV vaccine in the national immunisation programme and planned introductions, 2013. Available at: http://www. who.int/immunization/diseases/hpv/decision-implementation/en/. Accessed 13 October 2015
19. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30:F123-38
20. Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80
21. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015; 32:10-30
22. Hanquet G, Valencianob M, Simondonc F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine 2013; 31:5634-42
23. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009; 6:e1000097
24. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available at: http://www.consort-statement.org/. Accessed 1 November 2015
25. Garland SM, Brotherton JML, Condon JR, et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Medicine 2011; 9:104
26. Dorell CG, Jain N, Yankey D. Validity of parent-reported vaccination status for adolescents aged 13-17 years: National Immunization Survey-Teen, 2008. Public Health Rep 2011; 126:60-9
27. Brotherton JML, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014; 32:592-7
28. Osborne S, Tabrizi SN, Brotherton JML, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 2015; 33:201-8
29. Garland SM, Molesworth EG,Machalek DA, Cornall AM, Tabrizi SN. How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect 2015; 21:834-41
30. Novakovic D, Cheng A, Baguley K, et al. Juvenile recurrent respiratory papillomatosis: 10 year audit and Australian prevalence estimates. Laryngoscope 2016; doi:10.1002/lary.26005
31. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7:1-13
32. Bosch FX. Eradication of cervical cancer in Latin America. Salud Pública de México 2016; 58:97-100
33. Saville AM. Cervical cancer prevention in Australia: planning for the future. Cancer Cytopathol 2016; 124:235-40
34. Brotherton JML, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust 2016; 204:184-5
35. Bruni L.Worldwide surveillance of HPV vaccination coverages: the current picture [abstract MSS2-3]. In: EUROGIN (European Research Organisation on Genital Infection and Neoplasia) 2015 Congress, Sevilla, Spain, 5 February 2015
36. Arbyn M, Castellsague X, de Sanjose , et al. World-wide burden of cervical cancer in 2008. Ann Oncol 2011; 22:2675-83
37. World Health Organization. Weekly epidemiological record. Available at: http:// www.who.int/wer. Accessed 18 March 2016
38. Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34: 983-99
39. Garland SM, StanleyM, Brotherton J, et al. International Papillomavirus Society. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2016; 2:9-10
40. Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr 2016; 170:445-52